Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity

References

• Pi-Sunyer FX. Weight loss and mortality in type 2 diabetes. Diabetes Care 2000;23:1451-2
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4
   PubMed Web of Science ®Google Scholar
• Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 1999;22:33-7
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al.10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Okayasu S, Kitaichi K, Hori A, et al. The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. Biol Pharm Bull 2012;35:933-7
   PubMed Web of Science ®Google Scholar
• Kodama S, Saito K, Tanaka S, et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:959-65
   PubMed Web of Science ®Google Scholar
• Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101
   PubMed Web of Science ®Google Scholar
• Bavenholm PN, Efendic S. Postprandial hyperglycaemia and vascular damage – the benefits of acarbose. Diab Vasc Dis Res 2006;3:72-9
   PubMedGoogle Scholar
• Miyamura M, Schnell O, Yamashita C, et al. Effects of acarbose on the acceleration of postprandial hyperglycemia-induced pathological changes induced by intermittent hypoxia in lean mice. J Pharmacol Sci 2010;114:32-40
   PubMed Web of Science ®Google Scholar
• Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care 2011;34(Suppl 2):S120-S7
   PubMed Web of Science ®Google Scholar
• Godbout A, Chiasson JL. Who should benefit from the use of alpha-glucosidase inhibitors? Curr Diab Rep 2007;7:333-9
   PubMedGoogle Scholar
• Enc FY, Imeryuz N, Akin L, et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 2001;281:G752-63
   PubMed Web of Science ®Google Scholar
• Arakawa M, Ebato C, Mita T, et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 2008;57:1299-306
   PubMed Web of Science ®Google Scholar
• Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol 2014;2:46-55
   PubMed Web of Science ®Google Scholar
• World Health Organization: Definition,diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Geneva, World Health Organization, 1999
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
   PubMed Web of Science ®Google Scholar
• Li Y, Mu Y, Ji Q, et al. Hypoglycaemia, abnormal lipids, and cardiovascular disease among Chinese with type 2 diabetes. Biomed Res Int 2015;2015:862896
   PubMed Web of Science ®Google Scholar
• Ma RC. Acarbose: an alternative to metformin for first-line treatment in type 2 diabetes? Lancet Diabetes Endocrinol 2014;2:6-7
   PubMed Web of Science ®Google Scholar
• Mondal A, Guria T, Maity TK. A new ester of fatty acid from a methanol extract of the whole plant of Amaranthus spinosus and its alpha-glucosidase inhibitory activity. Pharm Biol 2015;53:600-4
   PubMed Web of Science ®Google Scholar
• Nowotny B, Zahiragic L, Bierwagen A, et al. Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: a randomised feasibility trial. Diabetologia 2015;58:255-64
   PubMed Web of Science ®Google Scholar
• Nwosu BU, Maranda L, Cullen K, et al. A randomized, double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight/obese youth with type 1 diabetes. PLoS One 2015;10:e0137525
   PubMed Web of Science ®Google Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26:881-5
   PubMed Web of Science ®Google Scholar
• Leiter LA, Ceriello A, Davidson JA et al.; International Prandial Glucose Regulation Study Group. Postprandial glucose regulation: new data and new implications. Clin Ther 2005;27(Suppl B):S42-S56
   PubMed Web of Science ®Google Scholar
• Sugihara H, Nagao M, Harada T, et al. Comparison of three alpha-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes. J Diabetes Investig 2014;5:206-12
   PubMed Web of Science ®Google Scholar
• Tanaka K, Saisho Y, Kawai T, et al. Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. Endocr J 2015;62:399-409
   PubMed Web of Science ®Google Scholar
• Tanaka K, Saisho Y, Manesso E, et al. Effects of liraglutide monotherapy on beta cell function and pancreatic enzymes compared with metformin in Japanese overweight/obese patients with type 2 diabetes mellitus: a subpopulation analysis of the KIND-LM randomized trial. Clin Drug Investig 2015;35:675-84
   PubMed Web of Science ®Google Scholar
• Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu 2007;1:13-20
   Google Scholar
• Chan JC, Deerochanawong C, Shera AS, et al. Role of metformin in the initiation of pharmacotherapy for type 2 diabetes: an Asian-Pacific perspective. Diabetes Res Clin Pract 2007;75:255-66
   PubMed Web of Science ®Google Scholar
• Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005:Cd003639
   PubMed Web of Science ®Google Scholar
• Heppner KM, Perez-Tilve D. GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front Neurosci 2015;9:92-102
   Web of Science ®Google Scholar
• Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007;28:84-116
   Google Scholar
• D’Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metabol 2011;13(Suppl 1):126-32
   PubMed Web of Science ®Google Scholar
• Kawamori D, Kulkarni RN. Insulin modulation of glucagon secretion: the role of insulin and other factors in the regulation of glucagon secretion. Islets 2009;1:276-9
   PubMed Web of Science ®Google Scholar
• Kawamori D, Kurpad AJ, Hu J, et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab 2009;9:350-61
   PubMed Web of Science ®Google Scholar
• Meier JJ, Ueberberg S, Korbas S, Schneider S. Diminished glucagon suppression after beta-cell reduction is due to impaired alpha-cell function rather than an expansion of alpha-cell mass. Am J Physiol Endocrinol Metab 2011;300:E717-23
   PubMed Web of Science ®Google Scholar
• Robson-Doucette CA, Sultan S, Allister EM, et al. Beta-cell uncoupling protein 2 regulates reactive oxygen species production, which influences both insulin and glucagon secretion. Diabetes 2011;60:2710-19
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20
   PubMed Web of Science ®Google Scholar
• Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644-55
   PubMed Web of Science ®Google Scholar
• Yan M, Mehta JL, Zhang W, Hu C. LOX-1. Oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications. Cardiovasc Drugs Ther 2011; 25:451-9
   PubMed Web of Science ®Google Scholar
• Sasaki S, Inoguchi T. The role of oxidative stress in the pathogenesis of diabetic vascular complications. Diabetes Metab J 2012;36: 255-61
   PubMedGoogle Scholar